Published on : May 31, 2016
ALBANY, New York, May 31, 2016: The report is added to the website’s vast pool of market intelligence reports on the healthcare industry. It analyzes the global migraine market and its current scenario. The report aims to provide a holistic view of the global migraine market and its scope of development over the coming years. It takes into account the various drivers, restraints, and market trends that influence the supply and demand chains of migraine treatment and therapies. Additionally, the report addresses the competitive landscape of the global migraine market by providing player profiles of the top names in this market.
According to the report, one of the key drivers of the global migraine market is the launch of new therapies. The global migraine market is expected to show a moderate growth rate over the coming years through the introduction of these new therapies, coupled with the growing use of drug treatment for migraines across the world. The global migraine market is also being propelled by a consistent growth in awareness levels among patients and doctors, regarding all available treatments.
Another factor that needs to be considered as an influence on the global migraine market’s growth rate is the growing female population across the world. Research shows that estrogen levels play a major part in the formation of migraines, both with and without auras. On an average, three women may suffer from migraines in their life to one man. Therefore, keeping in mind the growing global female population and a higher awareness regarding migraines and their treatment, the global migraine market is expected to gain demand in an incremental manner.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=720347
The report sheds light on the two most common drugs taken for the treatment of migraines: Ergots and Triptans. The pipeline for migraine treatment shows the development of multiple branded drugs that prove to be more effective and safer. These drugs in development are the source of major opportunities for investors and other players. New drugs and treatment are increasingly focusing on aiming at the source of migraines. The intention is to either cure them completely or to reduce the frequency and severity to a tolerable level.
Other drivers of the global migraine market include negative lifestyle options, such as the growing levels of career and financially-based stress levels, and the increasing number of people consuming toxins such as tobacco and alcohol. Both are known causes of migraines in those who suffer from them.
However, the global migraine market is currently restricted to a large extent by the health complications associated with the use of Triptans. The side effects of using Triptans can be severe for certain individuals, creating a reduction in their sales. The global migraine market is also majorly restricted by the limitations faced by medical personnel regarding the treatment of migraines in people who are also suffering from cardiovascular issues. The market is also hindered by a growing rate of consumption of OTC drugs.
Key players in the global migraine market include AstraZeneca, Eli Lilly and Company, Teva Pharmaceuticals, and Amgen, Inc.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org